ArticleInternational journal of general medicine2025
Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing IBD Management: A Literature Review on the Role of Non-Invasive Blood-Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment.Clinical and translational science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and safety of vedolizumab plus glucocorticoids versus infliximab in severe ulcerative colitis for optimized treatment selection. Methods: Patients admitted to the Department of Gastroenterology of Xinjiang Uygur Autonomous Region People's Hospital with confirmed diagnosis of ulcerative colitis from January 2020 to December 2022 were collected, and according to the biologics used, the patients were divided into Vedolizumab combined with glucocorticoids group (n = 23) and infliximab group (n = 23). Clinically relevant indicators of the patients were retrospectively analyzed. Results: The difference between the basic information of the two groups of patients before treatment was not significant ( Conclusion: Vedolizumab and infliximab are effective for severe UC, but vedolizumab with glucocorticoids outperforms infliximab in clinical response, remission, and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.